These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 8925884

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
    Lundgren CH, Sawa H, Sobel BE, Fujii S.
    Circulation; 1994 Oct; 90(4):1927-34. PubMed ID: 7923681
    [Abstract] [Full Text] [Related]

  • 24. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
    Okusa Y, Ichikura T, Mochizuki H, Shinomiya N.
    Int J Oncol; 2000 Nov; 17(5):1001-5. PubMed ID: 11029504
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas.
    Ulisse S, Baldini E, Mottolese M, Sentinelli S, Gargiulo P, Valentina B, Sorrenti S, Di Benedetto A, De Antoni E, D'Armiento M.
    BMC Cancer; 2010 Apr 19; 10():151. PubMed ID: 20403162
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Differential expression of urokinase-type plasminogen activator, its receptor, and inhibitors in mouse skin after exposure to a tumor-promoting phorbol ester.
    Lund LR, Eriksen J, Ralfkiaer E, Rømer J.
    J Invest Dermatol; 1996 Apr 19; 106(4):622-30. PubMed ID: 8617995
    [Abstract] [Full Text] [Related]

  • 32. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T.
    Hiroshima J Med Sci; 2000 Mar 19; 49(1):67-72. PubMed ID: 10824459
    [Abstract] [Full Text] [Related]

  • 33. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
    Chambers SK, Gertz RE, Ivins CM, Kacinski BM.
    Cancer; 1995 Apr 01; 75(7):1627-33. PubMed ID: 8826920
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 36. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
    Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA.
    J Cell Physiol; 2003 Oct 01; 197(1):131-8. PubMed ID: 12942549
    [Abstract] [Full Text] [Related]

  • 37. Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell.
    Reeder JA, Dickinson JL, Chenevix-Trench G, Antalis TM.
    Teratog Carcinog Mutagen; 1993 Oct 01; 13(2):75-88. PubMed ID: 8102211
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH.
    Cancer Res; 2003 Aug 01; 63(15):4648-55. PubMed ID: 12907645
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.